<DOC>
	<DOCNO>NCT01565356</DOCNO>
	<brief_summary>This study re-read 10-minute positron emission tomography ( PET ) scan acquire previous clinical study AV-45 30 50 minute injection compare result .</brief_summary>
	<brief_title>Evaluation PET Scan Timing Relative AV-45 Injection Time</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Eligibility subject scan use study determine subject 's eligibility/enrollment Study A01 ( NCT01565291 ) A03 ( NCT01565330 ) . Inclusion Criteria ( AD group ) : Greater 50 year age Probable AD accord National Institute Neurological Communication Disorders StrokeAlzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria Mild/moderate dementia evidence MiniMental State Examination ( MMSE ) score range 10 24 , boundary include , screen History cognitive decline gradual onset progressive period least 6 month Inclusion Criteria ( A01 [ NCT01565291 ] healthy volunteer group ) : 50 year age , inclusive MMSE 29 great Inclusion Criteria ( A03 [ NCT01565330 ] healthy volunteer group ) : 35 55 year age , inclusive MMSE 29 great Exclusion Criteria ( group ) : Neurodegenerative disorder AD , include , limited Parkinson 's disease , Pick 's disease , frontotemporal dementia , Huntington 's chorea , Down syndrome , CreutzfeldtJacob disease , normal pressure hydrocephalus , progressive supranuclear palsy Diagnosis dementing / neurodegenerative disease Diagnosis mixed dementia Cognitive impairment result trauma , hypoxic damage , vitamin deficiency , brain infection , brain cancer , endocrine disease , mental retardation Clinically significant infarct possible multiinfarct dementia define NINCDS criterion Evidence screen MRI biomarker suggest alternate etiology cognitive deficit ( healthy control , evidence suggest presence AD pathology ) Clinically significant psychiatric disease History epilepsy convulsion Clinically significant hepatic , renal , pulmonary , metabolic , endocrine disturbance Current clinically significant cardiovascular disease Received investigational medication within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Amyloid imaging</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>18F-AV-45</keyword>
	<keyword>florbetapir F 18</keyword>
	<keyword>Diagnostic imaging</keyword>
</DOC>